Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
KalVista Pharmaceuticals, Inc. (KALV) had Return on Tangible Equity of -54.75% for the most recently reported fiscal quarter, ending 2025-04-30.
| Income Statement Financials | |
-- |
|
$-52.22M |
|
-- |
|
-- |
|
$55.03M |
|
$-55.03M |
|
$1.95M |
|
$-53.08M |
|
$-53.08M |
|
$-52.22M |
|
$-52.22M |
|
$-52.22M |
|
$-52.22M |
|
$-55.03M |
|
$-54.77M |
|
49.65M |
|
49.65M |
|
$-0.99 |
|
$-0.99 |
|
| Balance Sheet Financials | |
$241.69M |
|
$1.99M |
|
$9.08M |
|
$250.77M |
|
$45.17M |
|
-- |
|
$110.21M |
|
$155.38M |
|
$95.39M |
|
$95.39M |
|
$95.39M |
|
49.76M |
|
| Cash Flow Statement Financials | |
$-152.91M |
|
$91.02M |
|
$159.73M |
|
$31.79M |
|
$132.27M |
|
$100.48M |
|
$12.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-153.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.75% |
|
|
Return on Tangible Equity |
-54.75% |
-20.83% |
|
-54.75% |
|
$1.92 |
|
$-3.10 |
|
$-3.08 |
|